Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  

| More

Dr Lal PathLabs - Q1 FY22 first cut - Beat across the board - YES Securities

Posted On: 2021-08-02 16:14:41 (Time Zone: UTC)

- Revenues at Rs6bn, up 41% qoq and not comparable yoy due to a suppressed base; COVID contributes 36% to Q1 sales with 1.1mn RT PCR tests

- Most of the COVID revenues in Apr-May with June contributing just Rs270mn

- Non COVID business up 87% yoy; Margin up ~300bps qoq despite higher COVID sales than Q4

Call Highlights

- Non COVID revenues has been subdued; never seen May month revenue below April in last 15 years which has occurred in Q1

- Volatility in non COVID business due to high infections resulting in more tests being prescribed

- Handled 5.9mn COVID patients in Q1


- M&A would go up in areas where DLPL is weaker

- Consumer shift - lot of tests getting consumed online which is a shift from earlier only offline pattern

- Lot of volatility in sales leading to mismatch on valuation expectation in M&A conversation between listed and unlisted players

- Shortage of manpower may lead to rise in staff costs for smaller cos which would shift share to organized market

- Aggregators can be very useful in markets where Dr Lal does not have physical presence

- Not looking at medicine delivery right now though aware new competition is offering a holistic OPD + diagnostic + medicine model

- Few quarters down, expect a more normal wave of growth

Cost & Realization

- Not taken price increases in last 5-6 years

- Home collection costs - net basis it does not increase as lower productivity of phlebotomist (8-10 samples vs 30-40 for walk ins) is offset by savings in real estate, maintenance costs

- Competition for phlebotomist and other quality manpower would go up so needs to watched

Revenue & Margin

- Revenues should come back to pre COVID level trajectory

- Margin should normalize at a higher level due to operating leverage but not at current level

- 12-13% revenues come from home collections

Shares of Dr. Lal Pathlabs Limited was last trading in BSE at Rs. 3716 as compared to the previous close of Rs. 3554.55. The total number of shares traded during the day was 29516 in over 4873 trades.

The stock hit an intraday high of Rs. 3773.35 and intraday low of 3573.45. The net turnover during the day was Rs. 108952363.

Source: Equity Bulls

Click here to send ur comments or to

Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only., its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.

Other Headlines:

Automobile Sector - Monthly Quick View - Aug'21 - Mixed Performance across Segments - Reliance Securities

Axis Securities initiating coverage on ICICI Securities

Company Update - Minda Corporation - Q1FY22 - ICICI Direct

Quant Pick - PVR Ltd - ICICI Direct

Quant Pick - ONGC - ICICI Direct

Peak in the headline wholesale inflation is behind us - WPI August 2021 - Acuité Ratings

Sansera Engineering - IPO - Strong Outlook with Steady Cash Flow - Reliance Securities

APL Apollo Tubes - Journey from a semi-commodity player to a branded one - HDFC Securities

Nazara Technologies Ltd - Upbeat in medium-term, Uncertain over Long-term - YES Securities

IPO Review - Sansera Engineering Ltd - ICICI Direct

Overall index is still 0.3% lower than the pre-pandemic levels - IIP July 2021

YES SECURITIES on Monthly General Insurance & Mutual Funds Data

India urban logistics spaces expected to cross 7 million sq. ft by 2022: JLL

Neogen Chemicals - Breaking into the next orbit with a bang - HDFC Securities

Gladiator Stocks - Bharti Airtel Ltd - ICICI Direct

Gladiator Stocks - V-Guard - ICICI Direct

Balkrishna Industries - Industry export growth accelerates - ICICI Securities

HDFC Life Insurance - Exide Life Acquisition - Maintain ADD - YES Securities

Gladiator Stocks - Grindwell Norton - ICICI Direct

Gladiator Stocks - Godrej Properties - ICICI Direct

Monthly Auto Volumes - August 2021 - ICICI Direct

Stock Tales - Easy Trip Planners - ICICI Direct

IPO Review - Vijaya Diagnostic Centre Ltd - ICICI Direct

AU Small Finance Bank - Attrition at top level remains key challenge; business momentum sustained in Jul/Aug'21 - ICICI Securities

Gladiator Stocks - State Bank of India - ICICI Direct

Gladiator Stocks - PNC Infratech - ICICI Direct

Vijaya Diagnostic Centre Ltd - IPO Note - YES Securities

Consumer Durables Sector - Lockdown mars performance yet again - Institutional Research Desk at HDFC Securities

75% of the employees today want to be in office at least once a week as compared to 52% in October 2020: JLL

Gladiator Stocks - Safari Industries - ICICI Direct

Gladiator Stocks - Interglobe Aviation - ICICI Direct

IPO Review - Ami Organics Ltd - ICICI Direct

Q1FY22 GDP - 31st Aug 2021 - Acuité Ratings & Research

Avanti Feeds - Higher input prices hurt margins - ICICI Securities

Company Update - Restructuring - Aarti Industries - ICICI Direct

Q1FY22 Company Update - MM Forgings - ICICI Direct

Company Update - Arvind Fashions - ICICI Direct

Zomato - Can margins and multiples surprise? - ICICI Securities

Ujjivan Small Finance Bank - Top management change and lumpy provisioning concern to weigh on valuation in near term - ICICI Securities

Bharat Dynamics - Guided missile systems to drive orderbook and profit growth - ICICI Securities

Economy - Continued accommodation necessary despite inflationary risks: MPC minutes - ICICI Securities

InterGlobe Aviation - Annual report analysis: Liquidity management remains the mainstay in anticipation of traffic recovery - ICICI Securities

General insurance - Health remains dominant growth driver; Strong all-round performance by Bajaj Allianz - ICICI Securities

Earnings Wrap Q1FY22: Resilient earnings, limited impact of second Covid wave - ICICI Direct

Fine Organic Industries Results Review - In-line performance - HDFC Securities

Power Plus Sector Update - July witnessed strong ~10% generation growth - HDFC Securities

Information Technology Sector Update - 'Hit Refresh' - HDFC Securities

Maintain ADD on JK Cement - Healthy performance - HDFC Securities

Maintain BUY on Star Cement - Margin recovers on pricing gain - HDFC Securities

Maintain BUY on Sadbhav Engineering - Long road to recovery - HDFC Securities

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020